The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) Study
University of Wisconsin, Madison · with National Institute of Allergy and Infectious Diseases (NIAID) · NCT07342582
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Up to age 17 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 670
- US sites recruiting
- 1
- Study start
- August 4, 2026
- Record last updated
- August 10, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17.5 years will be enrolled for age-match comparison with the older hospitalized cohort.
Being studied: Nasal Swab Healthy Surveillance; Nasal Swab Sick Samples; Nasal Swab Hospitalized Cohort; Sick Follow-up Survey; Older Cohort Control Group; Procedural Comfort or Care
Conditions: Rhinovirus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria (Aim 1 and Aim 2b Community Groups):
- Parent/legal guardian is willing and able to provide informed consent in English.
- Willing to comply with all study procedures and be available for the duration of the study.
- Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment
- Older Community Group: Generally healthy children 5 to 17.5 years of age at the time of enrollment.
- Current patient within primary care system at UW Health
Inclusion Criteria (Aim 2a: Hospitalized Group):
- Parent/legal guardian is willing and able to provide informed consent in English.
- Admitted to American Family Children's Hospital (AFCH) within the past 24 hours
- Children under 17.5 years of age at the time of enrollment
- Has a diagnosis of bronchiolitis, asthma exacerbation, acute hypoxemic respiratory failure or community acquired pneumonia (CAP) OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission
Exclusion Criteria (all participants):
- Congenital or currently acquired immunosuppressive condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)
- Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)
- Presence of tracheostomy or gastrostomy tube
- Previously enrolled a different group in the study
- Other child in the same household already enrolled in the study
- Not suitable for study participation due to other reasons at the discretion of the investigators.
Exclusion Criteria (Aim 1: Community Group Only):
- History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary)
- Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment
Exclusion Criteria (Aim 2: Hospitalized Group Only):
- History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)
- A positive test for any virus other than RV within the 48 hours prior to and including admission.
- Non-respiratory infection at the time of admission
- Neurologic disease (for example, cerebral palsy, genetic neurologic diseases, seizure disorder)
Exclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):
- Born prematurely, less than 32 weeks 0 days gestational age
Recruiting US locations
University of Wisconsin
Madison, WI 53792
Study contacts (from the official record)
- Research Nurses · 608-228-4940 · reserachnurses@pediatrics.wisc.edu
Similar studies in Wisconsin
All healthy volunteers studies in Wisconsin →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How ASP3082 is Processed in Healthy Men
Astellas Pharma Global Development, Inc.
- Location
- Madison, WI
- Eligibility basics
- Ages 18–65 · Men only
- RecruitingHealthy volunteersPhase 1
A Trial of Lu AH69593 in Healthy Participants
H. Lundbeck A/S
- Location
- Madison, WI
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- La Crosse, WI + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
Astria Therapeutics, Inc.
- Location
- Madison, WI + 2 other US sites
- Eligibility basics
- Ages 18–55